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Aim: To conduct a systematic review on the prevalence, risk factors, treatments and out-
comes of Coronary Artery Disease (CAD) in Indians.
Methods and results:We conducted a systematic review of studies in Indians with CAD from
Jan 1969 to Oct 2012.
Initial search yielded 3885 studies and after review 288 observational studies were
included. The prevalence of CAD in urban areas was 2.5%e12.6% and in rural areas, 1.4%
e4.6%. The prevalence of risk factors was: smoking (8.9e40.5%), hypertension (13.1e36.9%)
and diabetes mellitus (0.2e24.0%). The median time to reach hospital after an MI was
360 min. In hospital rates of drug use were: antiplatelets 68%e97.9%, beta blockers 47.3%
e65.8% and ACEIs 27.8e56.8%.
Conclusions: In this first systematic review of CAD in India, prevalence of risk factors is high,
treatments delayed and use of evidence based treatments variable.
Copyright © 2015, Cardiological Society of India. All rights reserved.macology, St. John's Medical College, Bangalore 560 034, India. Tel.: þ91 (0) 80 49466041;
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i n d i a n h e a r t j o u rn a l 6 7 ( 2 0 1 5 ) 3 0 2e3 1 0 3031. IntroductionThe burden of cardio vascular disease (CVD) is on the rise
globally. Cardiovascular deaths account for 30% of deaths
world wide.1 The burden of CVD is projected to be the highest
in India by the year 2020, as compared to other countries.2 In
the WHO-PREMISE study, the proportion of coronary heart
disease (CHD) among patients less than 50 years of age, was
highest in India (22.6% in males and 3% in females).3 In the
Million Death Study (2009) the authors determined that car-
diovascular diseases are the leading cause of death (20.3% in
males and 16.9% in females) among Indian adults (age 25e69
years).4 Yet it is difficult to get a comprehensive picture of the
epidemiology and disease burden of coronary artery disease
(CAD) in India. One systematic review of 31 studies in India
reported that the prevalence of CAD is higher in urban as
compared to the rural areas (Men 35e90/1000 vs. 17e45/1000;
Women 28e93/1000 vs. 13e43/1000).5
In order to implement nation-wide policies to control CAD,
we need a comprehensive view of its different aspects such as
the disease burden, manifestations, treatment patterns and
outcomes of the condition. We therefore conducted a sys-
tematic review of all the observational studies to record the
available evidence on the epidemiology, risk factors, clinical
presentations, management and outcomes of coronary artery
disease among Indians residing in India.2. Methods
A systematic review of all studies in Asian Indians with cor-
onary artery disease addressing the epidemiology, risk fac-
tors, clinical presentations, management or outcomes of CAD
among Indians.
2.1. Studies included
We included all studies from January 1969 to October 2012,
pertaining to coronary artery disease and its treatments. The
diagnosis of coronary artery disease was not uniform across
different studies. The diagnosis was based on history of
angina or myocardial infarction or electrocardiographic find-
ings. Treatment of CAD included both prescribed drugs (in
hospital based studies) and self-reported use of medications
(in community based studies). We only included studies in
English. As English is the primary medium of scientific
communication in India, we are confident that we have been
able to include all the relevant studies in this review. Amongst
the studies that were excluded were: articles without original
data (letters to the editor, comment and narrative review);
studies conducted among Indians residing outside India and
international studies without separate data on Indians.
2.2. Search strategy and data extraction
Two independent reviewers conducted a systematic search of
Medline as well as extensive hand searches using the
following pre-specified MeSH terms and search strategies:
Search #1: Heart diseases OR myocardial ischemia ORcoronary disease OR coronary artery disease OR coronary
arteriosclerosis OR coronary atherosclerosis OR Ischemic
Heart Disease; Search # 2: India OR Indians OR South Asia; and
Search #3: combined #1 and # 2.
Duplicates were removed using Reference Manager
(version 12). Relevant studies were selected for data extraction
based on pre-specified eligibility criteria. Disagreements be-
tween the two reviewers on the selection of articles were
resolved by discussions with a third reviewer.
We assessed study quality using parameters specified in
the STROBE statement.6 The parameters for different obser-
vational study designs were specified and are described here.
For cohort studies we used indicators of eligibility criteria,
source of cohort, methods of selection, and methods of follow
up. The maximum score was 4 and minimum was 0. For
caseecontrol and cross-sectional studies the parameters
included were as follows: eligibility criteria, ascertainment of
cases and controls and the rationale for the choice of cases
and controls. For cross sectional studies, eligibility specified,
ascertainment of cases and rationale for inclusion of cases,
were the parameters. The maximum score possible was 3 and
the minimumwas 0. Using a structured format, the following
data were independently extracted: year, type of study, sam-
ple size, patient characteristics, incidence, prevalence, risk
factors, manifestations, treatments and outcomes of CAD.3. Results
The initial search yielded 3885 studies. Of these, a total of 111
studies were excluded as they were either studies with In-
dians combined with other South Asians (20) or studies con-
ducted among Indians living outside India (91). We found 37
RCTs in our search and none of them looked at clinical out-
comes. After removing duplicates and reviewing the title and
abstract for relevance, 342 observational studies were identi-
fied. Fifty four of the 342 articles were editorials, letter to the
editor, comment and did not contain original data. We
extracted data from 288 observational studies (cohort 12
[4.2%], case control 57 [19.8%], cross sectional 180 [62.5%] and
mixed methods 39 [13.5%]) (Fig. 1). Of these there were suffi-
cient data in 59 studies for further analyses (Chi-squared and
time trend analysis).
3.1. Quality of the studies included (Table 1)
Among the observational studies (288), we were able to assess
the quality for 194 (68.3%) studies that had evaluable data. The
data were insufficient to assess the quality in other studies. Of
the 194 studies, 131 (67.5%) studies scored 2, and only 2 studies
(1.0%) obtained the maximum score of 4.
3.2. Incidence and prevalence of CAD
There were two community based studies that had data on
the incidence of CAD. The study by Chadha et al in 1993
conducted in urban Delhi included 4151 subjects (25e64 years
of age) and followed up for 3 years, reported an incidence of
CAD as 19.7/1000 (male 17.3 and female 21.0).7 The study by
Fig. 1 e Flow chart of included studies.
i n d i a n h e a r t j o u r n a l 6 7 ( 2 0 1 5 ) 3 0 2e3 1 0304Trivedi et al in rural population of Gujarat included 714 sub-
jects (30e62 years of age), followed up for 5 years estimated
the CAD incidence of 25.1/1000.8
There were 18 cross sectional studies conducted in various
parts of India between 1990 and 2012. In 12 of these studies
from urban areas among adults aged above 20 years
(1990e2012, sample size [SS] from 534 to 13,723), the preva-
lence ranged from 2.5% to 12.6%. In 7 of these studies in rural
areas (1993e2009, SS from 812 to 3148), the prevalence ranged
from 1.4% to 4.6%. The prevalence of CAD among males in
urban areas was 2.8 %e7.9% in 11 studies and 2.2%e15.8%Table 1 e Summary of Quality scores of Observational
studies.
Quality score Observational studies n ¼ 194 (%)
4 2(1.03)
3 49(25.2)
2 131(67.5)
1 12(6.1)among females in 9 studies (1990e2012). In rural areas the
prevalencewas 3.1%e6.9% inmales and 1.7%e4.6% in females
(1994e2009). There was a significant positive trend in the
overall prevalence of CAD in urban (ManteleHaenszel Chi
squared value 299.99, p < 0.0001) and rural areas (Man-
teleHaenszel Chi squared value 19.74, p < 0.0001). The diag-
nosis of CAD in these studieswas not uniform. It was based on
past history, ECG changes or the Rose questionnaire (Table 2).
Prevalence of CAD as reported by ECG changes, were low: 5.2%
in urban areas9 and 3.1e4.4% in rural areas.10e12
3.3. Risk factors (Table 3)
The studies reporting the prevalence of risk factors were from
1976 to 2012. Hence the definition for each of the risk factors is
different across various studies. The risk factor rates are thus
reported as minimum to maximum percentages in this study.
The prevalence of common risk factors in the community
from cross sectional studies were as follows: hypercholester-
olemia (7.0e30.0%; 10 studies 1994e2012), hypertension
(13.1e36.9%; 12 studies 1993e2012) diabetes mellitus
Table 2 e Studies reporting prevalence of CHD and criteria for diagnosis by year.
Authors Year Place S size Age (yrs) CHD % Male Female cCHD diagnosis criteria
Urban (U)
Chadha SL38a 1990 Delhi 13723 25e64 3.2 3.9 2.5 Clinical history
Chadha SL39a 1992 Delhia 1317 25e64 2.5 2.8 2.2 Clinical history
Gupta R9 1995 Jaipur 2212 20 7.6 6.0 10.4 Past doc, Rose q or ECG changes
5.2 3.5 8.4 Q, ST or T wave
bGupta R18 1996 Rsthan 3397 NA 4.5 6.0-U
3.4-R
NA Clinical history and ECG
RChdrn A40a 1998 Chennai 953 40 3.9 3.5 4.5 Clinical history or ECG (Q wave, ST changes)
Mohan V41a 2001 Chennai 1175 20 11 NA NA Clinical history or ECG (ST,T and Q changes
Gupta R42a 2002 Jaipur 1123 20 NA 6.2 10.1 Clinical history ± ECG (ST,T and Q changes)
Gupta R43a 2002 Rsthan 2212 >20 NA 7.1 H
1.8 M
10.4 H
6.6 M
Clinical history or ECG (ST and T changes)
D Prabhakaran28 2005 Delhi 2122 20e59 NA 7.3 NA Clinical history or ECG (ST, T and Q changes)
Latheef SA44a 2007 Tirupathi 1519 >20
M 42.5 ± 9.4
F 38.8 ± 11.2
12.6 6.8 15.8 Clinical history & ECG (ST or Q wave changes or T changes)
bKamili M45a 2007 Kashmiris 3128 40 7.5
8.4 U
6.7 R
7.9 6.6 Past doc, Rose q or ECG (ST and T changes)
Murthy PD46a 2012 AndraP 534 20 5.4 7.7 3.6 History or ECG (ST or Q wave changes)
Rural(R)
Kutti VR10 1993 Tpuram 1130 >25 1.4 NA NA Definitive evidence of CHD
Gupta R11 1994 C Rsthan 1150 53 ± 4.6 4.6 4.6 4.6 Clinical history ± ECG ST and T wave changes ± Rose Q
Wander GS12 1994 Punjab 1100 >30 3.2 3.1 3.4 History, ECG and TMT
Gupta R47a 1997 Rsthan 3148 20 NA 3.4 3.7 Clinical þ ECG (Q, ST or T changes)
Clara Chow48a 2007 AndraP 345 20e90 2.5 NA NA previous heart attack, stroke or angina
Rajeev B49a 2009 H Pradesh 812 >30 4.1 6.9 1.7 Hosp. records, TMT,ECG changes, Cor. Angiography
(ManteleHaenszel Chi squared value for urban 299.99, p < 0.0001) (ManteleHaenszel Chi squared value for Rural 19.74, p < 0.0001). NA: Not Available, H: Hindus, M: Muslims.
Rsthan e Rajasthan, C Rsthan e Central Rajasthan, Tpuram e Tiruvananthapuram, AndraP e Andhra Pradesh, H Pradesh e Himachal Pradesh.
Reference numbers 38ae49a are provided in the supplementary data.
a Gujaratis.
b Includes both urban and rural areas.
c Studies used different criteria for the diagnosis of CHD.
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Table 3 e Prevalence (in %) of risk factors for CHD among community and patients from various studies.
Risk factors Prevalence in
community %
No. of studies Prevalence in patients
from CS studies
No. of studies
Hypercholesterolemia 7.0e30.0 99,12,28,44a,50a53a,65a,66a 15.0e46.2 643a,55a58a,63a
Decreased HDL 31.0e55.0 542a,44a,51a,53a,66a NA
Increased TG 29.2e45.9 542a,44a,51a,53a,66a NA
Increased LDL 21.5e41.5 342a,53a,66a NA
Smoking 8.9e40.5 89,10,12,28,47a,48a,52a,53a,65a,66a 16.5e87.0 1022,24,25,57a59a,61a,63a,64a,67a
Hypertension 13.1e36.9 1110,12,28,42a,44a,47a,48a,51a53a,65a,66a 15.0e54.3 422,24,25,57a
Diabetes 0.2e24.0 119,10,12,28,42a,44a,47a,48a,52a,53a,65a,66a 5.0e44.6 522,24,25,57a,67a
Positive family history 17.0e19.4 252a,54a 8.0e40.0 357a,63a,68a
NA: Not Available.
CS: Cross sectional.
Reference numbers 42a,44a,47a,48a,50-59a,61a,63a,67e68a are provided in the supplementary data.
i n d i a n h e a r t j o u r n a l 6 7 ( 2 0 1 5 ) 3 0 2e3 1 0306(0.2e24.0%; 12 studies 1993e2012) and smoking (8.9e40.5%; 10
studies 1993e2012). Cross sectional studies among CAD pa-
tients report the prevalence of risk factors as follows: hyper-
cholesterolemia 15.0e46.2% (6 studies 1970e2004), smoking
16.5e87.0% (10 studies 1987e2008), hypertension 15.0e54.3%
(4 studies in 1987e2008) and diabetes mellitus 5.0e44.6% (5
studies 1987e2008). There was a significant positive trend
with common risk factors like smoking, hypertension, dia-
betes mellitus and dyslipidemia in males and females when
prevalence from studieswith uniformdefinition of risk factors
were analyzed. ManteleHaenszel Chi squared values for
males: Smoking 145.52, p < 0.0001, Hypertension 103.99,
p < 0.0001, Diabetes mellitus 12.64, p ¼ 0.0004, Dyslipidemia
161.09, p < 0.0001. ManteleHaenszel Chi squared values for
females: Smoking 35.84, p < 0.0001, Hypertension 35.59,
p < 0.0001, Diabetes mellitus 11.19, p ¼ 0.0008, Dyslipidemia
12.12, p ¼ 0.0005 (Table 4).
Of the 55 caseecontrol studies, the key risk factors (odds
ratio) were, diabetes mellitus (2.7e8.9; 5 studies
1996e2008),13e17 hypertension (2.0e4.6; 4 studies
1994e2005)11,13,14,16 and smoking (1.3e4.4; 6 studiesTable 4 e Prevalence of major risk factors (%) for CAD in comm
Author Year Sample size Age Smoking
M F
R Gupta9 1995 2212 20 39 19
R Gupta47a 1997 3148 20 51 5
Reddy N K52a 2002 3307 43.12 ± 9.5 27 2
R Gupta53a 2003 1123 NA 40.5 20
R Gupta65a 2007 1127 20 37 2
R Gupta66a 2012 739 20e59 21.1 4
NA: Not Available.
Reference numbers 47a, 52-53a, 65e66a are provided in the supplementa
Definitions of the risk factors.
Smoking: Users of all types of tobacco products and present & past smo
mention the definitions.
Hypertension: Blood pressure of >140/90 was considered as hypertension.
%.
Dyslipidemia: Total blood cholesterol levels 200 mg/dl.
ManteleHaenszel Chi squared values for males: Smoking 145.52, p < 0.000
Dyslipidemia 161.09, p < 0.0001.
ManteleHaenszel Chi squared values for females: Smoking 35.84, p < 0.00
Dyslipidemia 12.12, p ¼ 0.0005.1994e2005).11,13e16,18 On the other hand vegetarianism (0.3; 1
study, 1996) and higher socioeconomic status (0.32 vs lower; 1
study 1996)13 were found to be protective for CAD.
3.4. Studies on acute coronary syndrome (ACS)
We identified 19 studies on different aspects of acute coronary
syndrome. The studies included 51,077 patients with
myocardial infarction (minimum sample size [SS] 5519 and
maximum SS 25,74820) between 1972 and 2012.
3.5. Presentation and treatment
The mean age for the presentation of an acute myocardial
infarction (AMI) ranged from 47 to 60 yrs in 6 studies. Anterior
wall MI was the commonest presentation (50.5e71.7%, 3
studies, 1970e2008) and antero-inferior wall infarction was
the least common (2.2e3.9%, 2 studies 2004e2008) (Table 5).
The time taken for onset of symptoms to reach hospital
was reported to be over 24 h from a study conducted as early
as 1972 (Gupta RN, SS 165).21 This interval has considerablyunity from studies with similar definitions for risk factor.
Hypertension Diabetes Dyslipidemia
M F M F
30 34 NA NA NA NA
24 17 NA NA NA NA
28 19 26 9 59 45
.5 33.7 33.7 7.8 7.3 37.4 43.1
.1 57.9 48.9 25.9 21.1 32.6 39.5
.2 39.5 24.6 15.5 10.8 33 32.7
ry data.
kers are included in studies 53a, 65a and 66a. Other studies do not
Diabetes mellitus: Past history or fasting blood sugar level of >126mg
1, Hypertension 103.99, p < 0.0001, Diabetes mellitus 12.64, p ¼ 0.0004,
01, Hypertension 35.59, p < 0.0001, Diabetes mellitus 11.19, p ¼ 0.0008,
Table 5 e Data reporting the involvement and location of
myocardial wall in patients with myocardial infarction.
Myocardial wall Percentage of patients
Anterior wall MI55a,24,25 50.5%e71.7%
Inferior wall MI24,25 39.1%e47.3%
Ass. right ventricular or
Posterior wall MI55a,24,25
13.3 %e62.7%
Antero-inferior wall MI24,25 2.2%e3.9%
Reference number 55a is provided in the supplementary data.
Table 6 e Symptoms to hospital and door to needle time
in the treatment of acute myocardial infarction.
Study Sample Time to hospital Door to needle
Gupta RN 197221 165 24 H to 7 D NM
Gupta SP 198169a 158 4 H 55 min NM
Chopra KL 199023 330 NM 210 ± 64 min.
Anand SS 199770a 87 330(50e5760)min 30 (17e100) min
Malhotra S 200371a 104 8.5 ± 0.8 H 1.2 ± 0.1 H
Jose VJ 200425 1320 10.8 ± 12.4 h NM
Achari V 200824 862 29.2 ± 10.8 H NM
Xavier D 200822 20,468 360 min 50 (25e68) min
NM: Not Mentioned, H: hours, D: days.
Reference numbers 69a-71a are provided in the supplementary
data.
i n d i a n h e a r t j o u rn a l 6 7 ( 2 0 1 5 ) 3 0 2e3 1 0 307decreased in recent studies to a median of 360 min (Xavier D
2008, SS 20,468).22 The door to needle time also has decreased
over time from 210 min (Chopra KL 1990, SS 330)23 to 50 min
(Xavier D 2008, SS 20,468).22 Table 6.
Drug use in acute MI was reported since 1997 in 6 studies.
They included thrombolytics 24.7e73.0%, antiplatelets
68.0e97.9%, beta blockers 47.3e65.8%, angiotensin-converting
enzyme inhibitors (ACEI) 27.8e56.8%, nitrates 59.0e86.6% and
anticoagulants 70.0e81.3% (Table 7). The rates of percuta-
neous coronary intervention (PCI) were as follows: overall
rates 7.5e11.9%20,22 and in STEMI patients 1.4e12.9%.20,22,24
3.6. Outcomes (Table 8)
Our systematic review identified 8 studies from 1972 to 2012
with data on clinical outcomes in patients with MI. The
earliest study21(Gupta RN 1972, SS 165) reported a 13.8% in-
hospital mortality and a 2012 study reported 3.9%.20 Studies
in patients with STEMI reported all cause mortality of 16.9%24Table 7 e In-hospital and post discharge drug use in
patients with MI.
Drug Utilization in % Year
Thrombolytics22,24,67a,70a,72a,20 24.7e73 1997e2012
Beta blockers22,70a,72a,20 47.3e65.8 1997e2012
ACE inhibitors22,70a,72a,20 27.8e56.8 1997e2012
Aspirin22,70a,72a,20 68.0e97.9 1997e2012
Nitrates70a,20 59.0e86.6 1997,2012
Anticoagulants22,70a,20 70.0e81.3 1997,2012
Reference numbers 67a,70a and 72a are provided in the supple-
mentary data.in 2004 and 8.2% in 2012.20 D Xavier et al in a large study re-
ported the following rates of outcomes: death 6.7%, reinfarc-
tion 1.9% and stroke 0.5% at the end of onemonth after AMI.22
3.7. Secondary prevention of CAD
There were 4 studies that reported the drug utilization in
secondary prevention of CAD from 2005 to 2009. Three of
these studies reported drug utilization in outpatients while
the fourth was a survey in the community. The use of aspirin
82.5e94.5% vs. 14.0% and statins 38.4e69.0% vs. 5.0% was
higher among outpatients as compared to that in the com-
munity. The use of beta blockers ranged from 48.1 to 69.0%
and ACE inhibitors or ARBs 15.5e82.0% in outpatients
(Table 9).4. Discussion
In a comprehensive systematic review of CAD studies from
India published over 40 years, we reviewed 288 studies that
fulfilled the criteria for inclusion. Multinational studies
including patients from India but not reporting separate data
on Indians were not included.
We used the STROBE criteria to assess quality of the
studies. Overall the quality of the studies was poor. About
two-thirds of the observational studies had a score of 2 and
just 1.0% obtained a maximum score of 4.
We identified only 2 community based studies that re-
ported the incidence of CAD. Chadha (1985e87)7 reported an
annual incidence of 19.7/1000 over 3 years, and Trivedi8
(1987e92) reported 25.1/1000 over 5 years. These studies
were done in 2 regions (Delhi and Gujarat) and thus the find-
ings may not be applicable to the entire country.
We identified 18 studies on the prevalence of CAD (11
urban, 6 rural and 1 in both areas) conducted over 22 years
(1990e2012). During this time period, we note an increase in
the prevalence of CAD, both in urban (3.2% in 1990 to 12.6% in
2007) and rural areas (1.4% in 1993 to 4.0% in 2009). The in-
crease is seen in bothmales and females. Even though there is
an increased prevalence of CAD over the years, this data has
limitations as all these studies were confined to single regions
and none representative of the country. On comparison of this
prevalence data with the reports from US and the UK, we
found that rates are lower than those reported in Indian
studies. The AmericanHeart Association Statistics Committee
and Stroke Statistics Subcommittee reports an overall preva-
lence of CHD in the US as 7.9% (9.1% in males and 7.0% in
females) in 2006.26 In England, the British Heart Foundation
reported a prevalence of 6.5% in males and 4.0% in females in
2006.27 Themean age of patients withMI in India is also lower.
The studies reported the age ranging from 55.0 to 58.2 years in
males and 55.7e60 years in females. The US studies reported
an average age of the first MI of 65.8 for men and 70.4 years for
women.26
The common risk factors identified were smoking, hyper-
cholesterolemia, hypertension and diabetes. Even though the
studies are not representative of the country, we note an in-
crease in the prevalence of these risk factors in the commu-
nity from 199310 to 2005.28
Table 8 e Outcomes reported among AMI patients.
Study Year S size Outcome In hospital 30 day 6e36 months
Gupta RN21 1972 165 All cause mortality 13.8% NM NM
Chopra KL23 1990 330 Mortality 4.8% NM NM
Reinfarction NM NM 4.0%
Late mortality NM NM 1.8%
E. George72a 1999 1072 Death 13.6% NM NM
Cardiac failure 15.5% NM NM
Reinfarction 11.4% NM NM
II/III degree block 9.2% NM NM
Arrhythmia 7.2% NM NM
Kaul U19 2002 57 Composite of death, MI or revascularization NM 12.7% NM
aJose VJ25 2004 1320 Mortality 16.9% NM NM
Composite of death, MI, Recurrent angina NM 18.8% NM
Xavier D22 2008 20468 Death NM 6.7% NM
Reinfarction NM 1.9%
Stroke NM 0.5%
a Achari V24 2008 862 Mortality 12.4 NM NM
PP Mohanan20 2012 25748 Death 3.9 NM NM
Reinfarction 0.5 NM
Stroke 0.3 NM
NM: Not Mentioned.
Reference number 72a is provided in the supplementary data.
a Studies included only patients with STEMI.
i n d i a n h e a r t j o u r n a l 6 7 ( 2 0 1 5 ) 3 0 2e3 1 0308Between 1993 and 2005 we see an increase in the preva-
lence of smoking in communities from 21.9 to 36.0%. The
European Heart Survey (EHS)29 reported a prevalence of to-
bacco smoking of 29.4% in 2004 for the European Region and
Heart and Strokes updates 2010 reports 20.6% in 2008 in the
US.30 The prevalence rate of smoking in India is higher, even
in comparison with data from a developing country like the
Republic of Seychelles (17.5%).31 Prevalence of hypercholes-
terolemia (30%, Prabhakaran D 2005) among Indians was
higher compared to Seychelles (24.2%) but lower compared to
46.8% in the US.30 Hypertension (30.0%) among Indians was
lower as compared to reports from other regions (39.6% in
Seychelles 2004, 33.6% in the US). The prevalence of diabetesTable 9 e Drug use for secondary prevention of CAD.
Study Year S size Drugs % Patients (CI)
Mendis S3
Bulletin
of WHO
(PREMISE)
2005 1013 Aspirin
Beta blockers
ACEI
Statins
94.5%
48.1%
41.3%
38.4%
Gupta R73a
Outpatients
2009 406 Aspirin
Beta Blockers
ACEI
Statins
82.5% (78.2e86.2)
53% (48.1e57.9)
15.55 (12e19)
69% (61e77)
Joshi R74a
30 yrs
Community
survey
2009 4535 Aspirin
BP lowering
Lipid lowering
14%(10e18)
41%(36e47)
5%(3e7)
Sharma K75a
Stable CAD
patients
2009 2993 Aspirin
Beta Blockers
ACEI/ARBs
Statins
91%
69%
82%
69%
Reference numbers 73e75a are provided in the supplementary
data.mellitus has not only increased almost 4 folds over 12 years in
India (4e15%, 1993e2005) but also is higher as compared to
other regions (9.3% in Seychelles in 2004 and 7.7% in the US
2006).
The data from patients with CAD, as reported in a recent
study (Xavier D 2008), showed a higher prevalence of smoking
(40.2%) and diabetes mellitus (30.4%) as compared to Euro
Aspire III (smoking 17.0% and 25.0% diabetes) while the
prevalence of hypertension is lower (37.7% vs. 56.0%).32
In patients with MI, the time from onset of symptoms to
reach the hospital and door to needle has reduced consider-
ably over the years (1972e2008) from 24 h21 to 6 h22 and from
21023 to 50 min22 respectively. These intervals are still longer
as compared to recent reports from other countries (170 min
and 40 min in European Heart Survey 1, 2002,33 145 min and
37 min in EHS 2, 200434 and 139 min in STEMI and 191 min in
NSTEMI patients in GRACE registry 200235).
The utilization of drugs among CAD patients in hospital
was reported in 6 studies. The use of antiplatelets was good
(68.0e97.9%) whereas the use of other drugs like beta blockers
47.3e65.8% and ACEIs 27.8e56.8% were low in India when
compared to other countries (beta blockers 81.0%, ACEIs
66.0%).35
The utilization of drugs for secondary prevention is also
low in India. A study at the community level (Joshi R, 2009)
reports utilization of aspirin at 14.0% and lipid lowering
drugs at 5.0% for secondary prevention. This is low as
compared to the overall rates of drug use among patients
with CHD from the PURE study36 (antiplatelets 25.8% and
statins 16.7%). PURE study also reports low rates of drug use
in participants from low income countries which include
India (antiplatelet drugs 11.0%, ACE inhibitors or ARBs 6.5%
and statins 4.5%).
There were very few studies with data on outcomes in
patients with MI. In-hospital mortality after MI has decreased
i n d i a n h e a r t j o u rn a l 6 7 ( 2 0 1 5 ) 3 0 2e3 1 0 309from 13.3% in 1972, 13.6% in 1999 to 3.9% in 2012. Mortality in
STEMI patients was reported to be 12.4% in 200824 which
decreased to 8.2% in 2012.20 The mortality rates have reduced
over the years, but studies from developed countries report
lowermortality rates. A follow up of the patients in the GRACE
registry reported a decline in hospital mortality from 8.4% in
1999 to 4.6% in 2005.37
There are limitations in our systematic review. The search
was limited to PubMed. There is therefore a possibility that
we missed identifying some studies. Though 288 observa-
tional studies were reviewed, collation and analysis of data
could be conducted only from 59 studies. This is because data
from other studies were either incomplete or were primarily
from patients with other conditions (eg. diabetes, rheumatic
heart disease etc.) with only a mention of CAD. Even though
these studies looked at various aspects of CAD, the objectives
and the patient population included were different in each
study.5. Conclusions
This is the first systematic review of CAD in India that is
comprehensive and covers a wide range of issues. We have
found that single centre and regional studies report a high
prevalence of CAD and high rates of risk factors. Patients take
a long time to get to hospital, treatment for ACS is delayed, in-
hospital use of evidence-based treatments is variable and post
discharge rates of drug use are low. Hospital and short term
mortality rates in ACS patients are high in observational
studies. There are only a few high quality studies, and none
representative of the country. There are no long-term studies
to inform chronic management of CAD. Therefore to counter
the burgeoning epidemic of CAD in India, we urgently need
high quality, representative and long term studies addressing
different issues. These studies should lead to programs for the
reduction of risk factors and improved treatments to reduce
the burden of CAD in India.Funding
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